Skip to main content
SpringerLink
Log in

Ethical and scientific challenges of placebo control arms in clinical trials

  • Original Article
  • Published:
International Journal of Pharmaceutical Medicine Aims and scope Submit manuscript

Summary

The ethical and scientific issues in therapeutic and diagnostic clinical research that involve placebo treatment in a control group of patients has been a source of concern for some time. The Declaration of Helsinki in its 1996 amendment tried to clarify placebo usage in biomedical research but, in the opinion of many, it has confused the situation. This paper reviews several aspects of the use of placebos in clinical trials. After a brief historical background, the need for control groups in randomized clinical trials is presented. The placebo-control design raises questions of deception, of patient information and informed consent, of patient bias and unblinding from such information, and of withholding active treatment by randomized allocation of trial medication. There are a number of control group options that can fulfil ethical and scientific needs. Examples of such acceptable placebo treatment arms are given in clinical trials of depression, epilepsy, Alzheimer’s disease and other forms of dementia. Finally, a decision tree is offered and a possible rewording of the relevant clause in the Declaration of Helsinki.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

Similar content being viewed by others

References

  1. Taubes G. Use of placebo controls in clinical trials disputed. Science 1995; 267:25–26.

    Article  PubMed  CAS  Google Scholar 

  2. Rothman KJ, Michiels KB. The continuing unethical use of placebo controls. NEJM 331:394-398.

  3. Levine RJ. Proposed revisions to the declaration of Helsinki — will they weaken the ethical principles underlying human research? NEJM 1999; 341:527–531.

    Article  Google Scholar 

  4. Brennan TA. The need to revise the declaration of Helsinki. NEJM 1999; 34: 531–534.

    Google Scholar 

  5. World Medical Association Declaration of Helsinki as amended by the 48th World Medical Assembly, Somerset West, Republic of South Africa, October 1996.

    Google Scholar 

  6. Delay J, Pichot P. Medizinische Psychologie. Stuttgart: Thieme, 1973.

    Google Scholar 

  7. Pepper OHP. A note on the placebo. Am J Pharmacol 1945; 117: 409–412.

    Google Scholar 

  8. Beecher HK. The powerful placebo. JAMA 1955; 159:1602–1606.

    Article  CAS  Google Scholar 

  9. Moertel CG, Taylor WF, Roth A, Tyce FAJ. Who responds to sugar pills? Mayo Clin Proc 1976; 51:96–100.

    PubMed  CAS  Google Scholar 

  10. Shapiro AK. Factors contributing to the placebo effect. Their implications for psychotherapy. Am J Psychother 1961; 18: 73–88.

    Google Scholar 

  11. Shapiro AK and Morris LA. The placebo effect in medical and psychological therapies. In Carfield SL, Bergin AE, eds. Handbook of psychotherapy and behavior change, 2nd edn. New York: John Wiley, 1978: 369–410.

    Google Scholar 

  12. Leber P. Is there an alternative to the randomized controlled trial? Psychopharmacology Bulletin 1991; 27:3–8.

    PubMed  CAS  Google Scholar 

  13. Lasagna L. Testimony given at Hearings before the Subcommittee on Antitrust and Monopoly of the Committee on the Judiciary, United States Senate, 87th Congress, 1st Session S. Res. 52 on S. 1552: Part 1:282–283, 1961.

    Google Scholar 

  14. Leber PD. The implicit assumptions of active control trials (a critical examination). Controlled Clinical Trials 1983; 14:133.

    Google Scholar 

  15. Leber PD. Hazards of inference: the active control investigation. Epilepsia 1989; 30(S1): 57–63.

    Article  Google Scholar 

  16. Battezzati M, Tagliaferro A, de Marchi G. La legatura delle due arterie mammarie interne nei disturbi di vascolarizzazione del miocardio: nota preventiva relativa de primi dati sperimentali e clinici. Minerva Med 1955; 46:1178–1188.

    PubMed  CAS  Google Scholar 

  17. Ratcliff JD. New surgery for ailing hearts. Reader’s Digest 1957; 71:70–73.

    Google Scholar 

  18. Brill IC, Rosenbaum WM, Rosenbaum EE, Flanery JR. Internal mammary artery ligation. Northwest Medicine 1958; 57:483–486.

    PubMed  CAS  Google Scholar 

  19. Harken DE. Clinical conference: long-term management of patients with coronary artery disease. Circulation 1958; 17:945–952.

    Article  PubMed  Google Scholar 

  20. Kitchell JR, Glover RP, Kyle RH. Bilateral internal mammary artery ligation for angina pectoris. American Journal of Cardiology 1958; 1:46–50.

    Article  PubMed  CAS  Google Scholar 

  21. Cobb LA, Thomas GI, Dillard DH et al. An evaluation of internal-mammary-artery ligation by a double-blind technique. New England Journal of Medicine 1959; 260:1115–1118.

    Article  PubMed  CAS  Google Scholar 

  22. Diamond EG, Kittle CF, Crockett JE. Evaluation of internal mammary artery ligation and sham procedure in angina pectoris. Circulation 1958; 18:712–713.

    Google Scholar 

  23. ICH. Harmonised tripartite guideline for good clinical practice. UK: Brookwood Medical Publications, 1997.

    Google Scholar 

  24. Brewin TB. Consent to randomized treatment. Lancet 1982; ii:919–921.

    Article  Google Scholar 

  25. Levine RJ. The apparent incompatibility between informed consent and placebo-controlled clinical trials. Clinical Pharmacology and Therapy 1987; 42:247–249.

    Article  CAS  Google Scholar 

  26. Echt DS, Liebson PR, Mitchell LB et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. NEJM 1991; 324: 781–788.

    Article  PubMed  CAS  Google Scholar 

  27. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. NEJM 1992; 327:227–233.

    Article  Google Scholar 

  28. Brown WA. Predictors of placebo response in depression. Psychopharmacology Bulletin 1988; 24:14–17.

    PubMed  CAS  Google Scholar 

  29. Quitkin FM, Rabkin JG, Stewart JW et al. Heterogeneity of clinical response during placebo treatment. Am J Psychotherap 1991; 148:193–196.

    CAS  Google Scholar 

  30. Meinardi H. Clinical evaluation of antiepileptic drugs: Guidelines of the International League Against Epilepsy. In De Deyn PP, D’Hooge R, Schafer A, eds. The ethics of animal and human experimentation. London: John Libbey, 1994: 279–285.

    Google Scholar 

  31. Theodore WH, Rauberras RF, Porter RJ. Felbamate: a clinical trial for complex partial seizures. Epilepsia 1991; 32:392–397.

    Article  PubMed  CAS  Google Scholar 

  32. Schmidt D. Two antiepileptic drugs for intractable epilepsy with complex partial seizures. J Neurol Neurosurg Psychiat 1982; 45:1119–1124.

    Article  PubMed  CAS  Google Scholar 

  33. Gram L, Schmidt D. Innovative designs of controlled clinical trials in epilepsy. Epilepsia 1993; 34(S7):1–6.

    Article  Google Scholar 

  34. Bourgeois B, Leppik JF, Sackellares JC. Felbamate: a double-blind controlled trial in patients undergoing presurgical evaluation of partial seizures. Neurology 1993; 43:693–696.

    Article  PubMed  CAS  Google Scholar 

  35. Pledger GW, Kramer LD. Clinical trials of investigational antiepileptic drugs: monotherapy designs. Epilepsia 1991; 32:716–721.

    Article  PubMed  CAS  Google Scholar 

  36. Elwes RDC, Johnson AL, Reynolds EM. The course of untreatable epilepsy. BMJ 1988; 297:948–950.

    Article  PubMed  CAS  Google Scholar 

  37. Beghi L, Tognoni G. Prognosis of epilepsy in newly referred patients: a multicentre prospective study. Epilepsia 1988; 29:236–243.

    Article  PubMed  CAS  Google Scholar 

  38. Reynolds EH. The influence of antiepileptic drugs on the natural history of epilepsy. Epilepsy Research 1991; S3:15–20.

    Google Scholar 

  39. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J. A controlled trial of tacrine in Alzheimer’s disease. JAMA 1992; 268:2523–2529.

    Article  PubMed  CAS  Google Scholar 

  40. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatr Psychopharmacol 1998; 1: 55–65.

    CAS  Google Scholar 

  41. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI, Tacrine Study Group. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease. JAMA 1994; 271:985–991.

    Article  PubMed  CAS  Google Scholar 

  42. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996; 7:293–303.

    PubMed  CAS  Google Scholar 

  43. Rogers SL, Farlow MR, Doody RS, Hohs R, Friedhoff LT, Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology 1998; 50:136–145.

    Article  PubMed  CAS  Google Scholar 

  44. Watkins PB, Zimmerman HJ, Knapp MJ et al. Hepatotoxic effects of tacrine administration in patients with Alzheimer’s disease. JAMA 1994; 271:992–998.

    Article  PubMed  CAS  Google Scholar 

  45. Schneider LS, Pollock VE, Lyness SA. A meta-analysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990; 38:553–563.

    PubMed  CAS  Google Scholar 

  46. De Deyn PP, Rabheru K, Rasmussen A, Bocksberger JP, Dautzenberg PL, Eriksson S, Lawlor BA. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999; 53:946–955.

    Article  PubMed  Google Scholar 

  47. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry 1999; 60:107–115.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The author thanks the Flemish Ministry of Education, Born-Bunge Foundation, OCMW Medical Research Foundation, Neurosearch Antwerp and Belgian Foundation of Scientific Research FWO for their support. Thanks also to Dr B.A. Pickut for editing the manuscript.

Conflict of interest

No conflict of interest declared

Author information

Authors and Affiliations

  1. Department of Neurology, University of Antwerp, Universiteitsplein 1, 2610, Wilrijk-Antwerp, Belgium

    P. P. De Deyn

  2. Department of Neurology, General Hospital Middelheim, Universiteitsplein 1, 2610, Wilrijk-Antwerp, Belgium

    P. P. De Deyn

  3. Department of Neurochemistry and Behaviour, Born-Bunge Foundation, Universiteitsplein 1, 2610, Wilrijk-Antwerp, Belgium

    P. P. De Deyn

Authors
  1. P. P. De Deyn
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

De Deyn, P.P. Ethical and scientific challenges of placebo control arms in clinical trials. International Journal of Pharmaceutical Medicine 14, 149–157 (2000). https://doi.org/10.1097/00124363-200006000-00008

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1097/00124363-200006000-00008

Keywords

Search

Navigation